近年来，以胰高血糖素样肽-1受体激动剂和芬特明/托吡酯复方制剂为代表的减重药物，为青少年肥胖治疗带来了突破性进展, 其通过靶向食欲调控中枢或神经递质再摄取抑制，显著改善青少年肥胖的临床结局。不仅能有效减轻体重，还能改善胰岛素抵抗、血脂异常等代谢问题。然而，其长期安全性、成本可及性及个体化用药策略仍需完善。未来需推进长期随访研究，建立真实世界数据库以支持个体化用药。药物治疗应协同生活方式干预，构建“家庭-医疗-社会”三位一体管理模式，实现青少年肥胖的精准防控。
Abstract
In recent years, weight-loss medications such as glucagon-like peptide-1 receptor agonist, and PHEN/TPM have brought breakthrough progress in the treatment of adolescent obesity. By targeting appetite control centers or inhibiting neurotransmitter re-uptake, they significantly improve clinical outcomes in obese adolescents. These drugs not only effectively reduce body weight but also ameliorate metabolic issues such as insulin resistance and dyslipidemia. However, their long-term safety, cost accessibility, and individualized medication strategies still require improvement. Moving forward, it is necessary to advance long-term follow-up studies and establish real-world databases to support personalized treatment. Medication therapy should be integrated with lifestyle interventions, building a “family-medical-society” tripartite management model to achieve precise prevention and management of adolescent obesity.
关键词
青少年肥胖 /
减重药物 /
药物安全性 /
胰高血糖素样肽-1受体激动剂
Key words
adolescent obesity /
weight-loss pharmacotherapy /
drug safety /
glucagon-like peptide-1 receptor agonist
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ Bensignor MO, Kelly AS, Arslanian S. Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults［J］. Front Endocrinol,2022,13:1043650.DOI: 10.3389/fendo.2022.1043650.
［2］ Lister NB, Baur LA, Felix JF, et al. Child and adolescent obesity［J］. Nat Rev Dis Primers, 2023, 9(1): 24. DOI:10.1038/s41572-023-00435-4 .
［3］ Kelly AS, Armstrong SC, Michalsky MP, et al. Obesity in adolescents: A review［J］. JAMA, 2024, 332(9): 738-748. DOI:10.1001/jama.2024.11809.
［4］ Doyle WN, Reinhart N, Reddy NC, et al. Anti-obesity medication use for adolescent metabolic and bariatric surgery patients: A systematic literature review［J］. Cureus, 2023, 15(12): e50905. DOI:10.7759/cureus.50905 .
［5］ Ahmad NN, Robinson S, Kennedy-Martin T, et al. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review［J］. Obes Rev, 2021, 22(11): e13326. DOI:10.1111/obr.13326.
［6］ Son JE. Genetics, pharmacotherapy, and dietary interventions in childhood obesity［J］. J Pharm Pharm Sci, 2024, 27: 12861. DOI:10.3389/jpps.2024.12861 .
［7］ Calcaterra V, Rossi V, Mari A, et al. Medical treatment of weight loss in children and adolescents with obesity［J］. Pharmacol Res, 2022, 185: 106471. DOI:10.1016/j.phrs.2022.106471.
［8］ Cominato L, Franco R, Damiani D. Adolescent obesity treatments: news, views, and evidence［J］. Arch Endocrinol Metab, 2021, 65(5): 527-536. DOI:10.20945/2359-3997000000393.
［9］ Niechcial E, Wais P, Bajtek J, et al. Current perspectives for treating adolescents with obesity and type 2 diabetes: A review［J］. Nutrients, 2024, 16(23): 4084. DOI:10.3390/nu16234084.
［10］ Sundbom M, Jarvholm K, Sjogren L, et al. Obesity treatment in adolescents and adults in the era of personalized medicine［J］. J Intern Med, 2024, 296(2): 139-155. DOI:10.1111/joim.13816.
［11］ Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity［J］. N Engl J Med, 2022, 387(24): 2245-2257. DOI:10.1056/NEJMoa2208601.
［12］ Ahn YJ, Maya J, Singhal V. Update on pediatric anti-obesity medications-current landscape and approach to prescribing［J］. Curr Obes Rep, 2024, 13(2): 295-312. DOI:10.1007/s13679-024-00566-z.
［13］ Masarwa R, Brunetti VC, Aloe S, et al. Efficacy and safety of metformin for obesity: A systematic review［J］. Pediatrics, 2021, 147(3): e20201610. DOI:10.1542/peds.2020-1610.
［14］ Zhao G, Zhang Q, Wu F, et al. Comparison of weight loss and adverse events of obesity drugs in children and adolescents: A systematic review and Meta-analysis［J］. Expert Rev Clin Pharmacol, 2022, 15(9): 1119-1125. DOI:10.1080/17512433.
2022.2117152.
［15］ Kelly AS. Current and future pharmacotherapies for obesity in children and adolescents［J］. Nat Rev Endocrinol, 2023, 19(9):534-541. DOI:10.1038/s41574-023-00858-9.
［16］ Diene G, Angulo M, Hale PM, et al. Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity［J］. J Clin Endocrinol Metab, 2022, 108(1): 4-12. DOI:10.1210/clinem/dgac549.
［17］ Raman V, Gupta A, Ashraf A P, et al. Pharmacologic weight management in the era of adolescent obesity［J］. J Clin Endocrinol Metab, 2022, 107(10): 2716-2728. DOI:10.1210/clinem/dgac418.
［18］ Sharma S, Garfield AS, Shah B, et al. Current mechanistic and pharmacodynamic understanding of melanocortin-4 receptor activation［J］. Molecules, 2019, 24(10): 1892. DOI: 10.3390/molecules24101892.
［19］ Mital S, Nguyen HV. Cost-effectiveness of antiobesity drugs for adolescents with severe obesity［J］. JAMA Netw Open, 2023, 6(10): e2336400. DOI:10.1001/jamanetworkopen.2023.36400.
［20］ Shamim MA, Patil AN, Amin U, et al. Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity：A systematic review and network Meta-analysis［J］. Diabetes Obes Metab, 2024, 26(10): 4302-4317. DOI:10.1111/dom.15777.
